<DOC>
	<DOCNO>NCT02559830</DOCNO>
	<brief_summary>Evaluating safety efficacy Lentiviral Hematopoietic Stem Cell Gene Therapy advance stage Metachromatic Leukodystrophy adrenoleukodystrophy .</brief_summary>
	<brief_title>Autologous Hematopoietic Stem Cell Gene Therapy Metachromatic Leukodystrophy Adrenoleukodystrophy</brief_title>
	<detailed_description>This phase I/II protocol aim assessment safety efficacy arylsulfatase A（ARSA ) / adenosine-triphosphate-binding cassette , sub-family D ( ABCD1 ) gene transfer hematopoietic stem/progenitor cell treatment metachromatic leukodystrophy/adrenoleukodystrophy . Metachromatic Leukodystrophy ( MLD ) autosomal recessive Lysosomal Storage Disorder ( LSD ) characterize severe progressive dysmyelination affect central peripheral nervous system . Adrenoleukodystrophy ( also know X-linked adrenoleukodystrophy , ALD , X-ALD ) , disorder peroxisomal fatty acid beta oxidation result accumulation very-long chain fatty acid ( VLCFA ) tissue throughout body , cause mutation ABCD1.Both diseases characterize progressive neurodegenerative decline , lead devastate state without treatment . Hematopoietic cell transplantation ( HCT ) ineffective ameliorate patient ' phenotype delay disease evolution many patient . No evidence efficacy enzyme replacement strategy available moment . Transplantation genetically correct autologous hematopoietic stem cell ( HSC ) could represent novel potentially efficacious treatment MLD/ALD patient . Recently , Italian group conduct gene therapy clinical trial base autologous HSC advance generation lentiviral vector ( LV ) patient affect severe , early onset form disease ( ClinicalTrials.gov Identifier : NCT01560182 ) .The safety efficacy gene therapy approach MLD patient evaluated.During 3 year follow-up , report multilineage ARSA expression ability prevent correct neurological disease manifestations.However , pre-symptomatic late infantile/Pre- early-symptomatic early juvenile patient recruit trial . In case , MLD/ALD patient tend diagnose advanced stage , miss best timing curable HSC intervention . In study , intend recruit symptomatic patient transduce cluster differentiation 34 positive ( CD34+ ) HSC treatment . In treated patient , study short-term long-term safety administration autologous transduce HSC , long-term engraftment , expression vector-derived ARSA/ABCD1 , ability transduce cell provide clinical benefit patient . The treated patient follow 3 year thereafter monitor safety gene therapy additional 5 year . If successful , study provide key result safety efficacy gene therapy MLD/ALD patient .</detailed_description>
	<mesh_term>Adrenoleukodystrophy</mesh_term>
	<mesh_term>Leukodystrophy , Metachromatic</mesh_term>
	<criteria>Inclusion Criteria For MLD : 1 . Confirmed diagnosis MLD ARSA genetic diagnosis , MRI（Magnetic Resonance Imaging）and low ARSA A activity ( 20 % normal level ) ; 2 . The patient ' symptom lesion develop end stage MLD . Inclusion Criteria For ALD : 1 . Confirmed diagnosis ALD ABCD1 genetic diagnosis , abnormal MRI imaging , abnormal high level long chain fatty acid ( VLCFA ) adrenocorticotropic hormone ( ACTH ) ; 2 . The patient ' symptom lesion develop end stage ALD . Exclusion Criteria For MLD： 1 . No clinical symptom MLD ; 2 . ARSA activity &gt; 50 % compare healthy individual ; 3 . End stage MLD ; 4 . Other complication , ie . Cancer ; 5. human immunodeficiency virus（HIV） RNA and/or hepatitis C virus RNA and/or hepatitis B virus DNA positive patient ; 6 . Patients underwent allogenic hematopoietic stem cell transplantation evidence residual cell donor origin . Exclusion Criteria For ALD : 1 . No evidence brain lesion ; 2 . Normal level VLCFAs blood ; 3 . End stage ALD ; 4 . Other complication , ie . Cancer ; 5. human immunodeficiency virus（HIV） RNA and/or hepatitis C virus RNA and/or hepatitis B virus DNA positive patient ; 6 . Patients underwent allogenic hematopoietic stem cell transplantation evidence residual cell donor origin .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>